ElectronX Launches MISO and CAISO Contract Suites for Intraday Power Hedging
Derivatives for the four largest
MISO is the largest
With the addition of MISO and CAISO suites to its Electric Reliability Council of Texas (ERCOT) and PJM Interconnection (PJM) offerings, ElectronX now provides intraday power hedging opportunities for nearly 60 percent of all
"
ElectronX is the only
Available MISO instruments include three hubs (
Since its full launch in February, ElectronX trading activity has grown steadily. In May, average daily volume reached nearly 1 GWh, a 70 percent increase from April. A new single-day record of 1,839 contracts traded was set on
ElectronX has now launched intraday contract suites for the nation's four largest grid operators in less than 120 days, underscoring its rapid product development during a time of immense pressure for energy systems balancing data center and infrastructure demand, renewable asset intermittency, and battery storage integration. The exchange plans to list product suites for all remaining tradeable
About ElectronX
ElectronX (EXI), the first U.S.-regulated, direct-access power derivatives market, is the energy exchange created to address volatile short-term price exposure to electricity. Based in Chicago, ElectronX is helping to expand the nation's power grid by building the financial infrastructure and risk management tools necessary to support increased investment in energy generation, renewable resources, and battery storage technology. ElectronX is a Designated Contract Market (DCM) and Derivatives Clearing Organization (DCO), regulated by the U.S. Commodity Futures Trading Commission (CFTC). For more information, please visit electronx.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/electronx-launches-miso-and-caiso-contract-suites-for-intraday-power-hedging-302786289.html
SOURCE ElectronX
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- The Anime "KAGURABACHI" Casts Yuichi Nakamura as Soshiro Azami; Cast Comments, Character Visual & Trailer Revealed!
- Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
- Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share